450 related articles for article (PubMed ID: 22365926)
1. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
Seghatchian J; Tolksdorf F
Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
[TBL] [Abstract][Full Text] [Related]
3. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.
Prudent M; D'Alessandro A; Cazenave JP; Devine DV; Gachet C; Greinacher A; Lion N; Schubert P; Steil L; Thiele T; Tissot JD; Völker U; Zolla L
Transfus Med Rev; 2014 Apr; 28(2):72-83. PubMed ID: 24685438
[TBL] [Abstract][Full Text] [Related]
4. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
5. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
6. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
7. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
8. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
9. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products.
Pohler P; Müller M; Winkler C; Schaudien D; Sewald K; Müller TH; Seltsam A
Transfusion; 2015 Feb; 55(2):337-47. PubMed ID: 25134439
[TBL] [Abstract][Full Text] [Related]
10. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.
Steinmann E; Gravemann U; Friesland M; Doerrbecker J; Müller TH; Pietschmann T; Seltsam A
Transfusion; 2013 May; 53(5):1010-8. PubMed ID: 22905868
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model.
Pohler P; Lehmann J; Veneruso V; Tomm J; von Bergen M; Lambrecht B; Kohn B; Weingart C; Müller TH; Seltsam A
Transfusion; 2012 Nov; 52(11):2414-26. PubMed ID: 22404822
[TBL] [Abstract][Full Text] [Related]
12. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters.
Johnson L; Cameron M; Waters L; Padula MP; Marks DC
Vox Sang; 2019 Jan; 114(1):47-56. PubMed ID: 30499111
[TBL] [Abstract][Full Text] [Related]
13. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.
Mohr H; Steil L; Gravemann U; Thiele T; Hammer E; Greinacher A; Müller TH; Völker U
Transfusion; 2009 Dec; 49(12):2612-24. PubMed ID: 19682340
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates.
Kim S; Handke W; Gravemann U; Döscher A; Brixner V; Müller TH; Seltsam A
Transfusion; 2018 Mar; 58(3):758-765. PubMed ID: 29282743
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light.
Hobson-Peters J; Amarilla AA; Rustanti L; Marks DC; Roulis E; Khromykh AA; Modhiran N; Watterson D; Reichenberg S; Tolksdorf F; Sumian C; Seltsam A; Gravemann U; Faddy HM
Transfusion; 2023 Feb; 63(2):288-293. PubMed ID: 36573801
[TBL] [Abstract][Full Text] [Related]
16. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets.
Bashir S; Cookson P; Wiltshire M; Hawkins L; Sonoda L; Thomas S; Seltsam A; Tolksdorf F; Williamson LM; Cardigan R
Transfusion; 2013 May; 53(5):990-1000. PubMed ID: 22905813
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro.
Van Aelst B; Devloo R; Vandekerckhove P; Compernolle V; Feys HB
Transfusion; 2015 Oct; 55(10):2404-14. PubMed ID: 25912149
[TBL] [Abstract][Full Text] [Related]
18. Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system.
Gravemann U; Handke W; Müller TH; Seltsam A
Transfusion; 2019 Apr; 59(4):1324-1332. PubMed ID: 30588633
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light.
Faddy HM; Fryk JJ; Hall RA; Young PR; Reichenberg S; Tolksdorf F; Sumian C; Gravemann U; Seltsam A; Marks DC
Transfusion; 2019 Jul; 59(7):2223-2227. PubMed ID: 31050821
[TBL] [Abstract][Full Text] [Related]
20. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
